-
UPDATE: Piper Jaffray Upgrades Gilead Sciences to Overweight
Wednesday, June 29, 2011 - 7:31am | 129Piper Jaffray is out with its report today on Gilead Sciences (NASDAQ: GILD), upgrading GILD from Neutral to Overweight. In a note to clients, Piper Jaffray writes, "The deal with J&J for Prezista in our opinion is the first of many, with the two companies already negotiating deal for Prezista...
-
Piper Jaffray Upgrades Gilead Sciences To Overweight, Raises PT To $53
Wednesday, June 29, 2011 - 6:28am | 28Piper Jaffray has upgraded Gilead Sciences (NASDAQ: GILD) from Neutral to Overweight and has raised the price target from $42 to $53.
-
Edison Investment Provides Color on Ziopharm Oncology
Wednesday, June 29, 2011 - 6:03am | 97Edison Investment provided color on Ziopharm Oncology (NASDAQ: ZIOP). In a research report published today, Edison stressed its optimism about the company's long term outlook. In the report, Edison states, “Ziopharm has a catalyst on the horizon – the read out from the Phase III trial of...
-
Stocks to Watch for 6/29/11: Fresh 52 Week Highs and Lows
Wednesday, June 29, 2011 - 4:11am | 2861Stocks trading at or near 52-week highs and lows provide excellent trading opportunities, as volatility tends to increase at such levels. The following stocks hit new 52-week highs in Tuesday's trading session: 1) CIGNA (NYSE: CI): Shares of CIGNA hit a 52-week high of $51.16 in Tuesday's...
-
Top 4 Small-Cap Stocks In The Research Services Industry With The Highest Cash
Wednesday, June 29, 2011 - 12:46am | 127Below are the top small-cap research services stocks on the NYSE and the NASDAQ in terms of cash. Myriad Genetics Inc (NASDAQ: MYGN) had $361.22 million in total cash and no debt for the latest quarter. Acacia Research Corporation (NASDAQ: ACTG) had $313.61 million in total cash and no debt for...
-
EntreMed Enters into $7.5 Million Equity Facility and Initiates $1.1 Million Drawdown
Tuesday, June 28, 2011 - 5:00pm | 198EntreMed, Inc. (Nasdaq: ENMD) announced today that it has entered into a standby equity distribution agreement, with YA Global Master SPV Ltd., a fund managed by Yorkville Advisors, LLC. Under the SEDA, EntreMed has the option, at its sole discretion, to sell, from time to time, up to $7.5 million...
-
Progress Software Roll Over in the After-Hours
Tuesday, June 28, 2011 - 4:53pm | 257Shares of Progress Software (NASDAQ: PRGS) are falling in the after-hours following the release of its Q2 earnings results. Currently, shares are off by 5.67%, trading at $21.96; they closed the regular session higher by 0.17%, at $23.28. Progress Software reported Q2 GAAP EPS of $0.26, on a...
-
Money Flowing Into Regeneron Pharmaceuticals
Tuesday, June 28, 2011 - 1:39pm | 87Regeneron Pharmaceuticals (NASDAQ: REGN) is having a nice session on Tuesday, climbing 4% to $55.19. Volume has been rather anemic, however. Last week, an FDA panel recommended that the agency approve Regeneron's eye drug, VEGF Trap-Eye. The company currently has a market cap of $5.02 billion. The...
-
Options Brief: ARIAD Pharmaceuticals, Inc.
Tuesday, June 28, 2011 - 1:00pm | 79Shares of ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) are higher on the session by 2.65%, trading at $11.24. Overall put volume is now running at 4.15x the daily average, with 6% of all puts traded being purchases on the offer. 13,055 contracts have traded on the session so far. ARIAD...
-
Tuesday's Put/Call Ratio Leaders
Tuesday, June 28, 2011 - 12:24pm | 77Here are today's Put/Call Ratio leaders… 1. Lennar Corp. (NYSE: LEN) 12,357 puts, 316 calls 2. Rovi Corp. (NASDAQ: ROVI) 3,899 puts, 468 calls 3. Pandora Media (NYSE: P) 4,916 puts, 745 calls 4. Ariad Pharmaceuticals (NASDAQ: ARIA) 12,039 puts, 1,929 calls 5. Apollo Group (NASDAQ: APOL) 4,285 puts...
-
Q&A with Aethlon Medical CEO, Jim Joyce; The Potential for the Hemopurifier® Medical Device in Cancer Immunotherapy
Tuesday, June 28, 2011 - 12:21pm | 943Point Roberts, WA - June 28, 2011 - Investorideas.com, a leader in sector stock research presents a new interview in its series of biotech Q&A's, featuring Jim Joyce, CEO of Aethlon Medical (OTCBB: AEMD), discussing how the Hemopurifier® medical device can be used in Cancer Immunotherapy...
-
Puts Purchased on Theravance, Inc.
Tuesday, June 28, 2011 - 11:10am | 128Shares of Theravance, Inc. (NASDAQ: THRX) are higher on the session by 0.84%, currently trading at $21.70. The stock has been moving largely lower over the past three months and is currently trading below the 200-day moving average. Options traders are buying puts on the name today. Though action...
-
Rosetta Genomics and UC Davis Researchers to Develop and Validate microRNA Biomarker to Predict Response to Neoadjuvant Chemotherapy in Bladder Cancer
Tuesday, June 28, 2011 - 10:15am | 217Rosetta Genomics (NASDAQ: ROSG) announces it has entered into a collaboration with the University of California, Davis to develop and validate a microRNA profile for muscle-invasive bladder cancer (MI-BC) that is predictive of patient response to neoadjuvant chemotherapy. The collaboration allows...
-
DARA BioSciences Spiking Higher after Positive Phase I Results
Tuesday, June 28, 2011 - 9:35am | 73Today DARA BioSciences (Nasdaq: DARA) announced the positive results of a randomized, placebo-controlled, double-blind, escalating single-dose study to evaluate the safety, tolerability, pharmacokinetics and food effect of DB959Na in healthy male and female volunteers. The presentation provided...
-
Citi Provides Color on Amylin Pharmaceuticals
Tuesday, June 28, 2011 - 9:05am | 152Citi provided color on Amylin Pharmaceuticals (NASDAQ: AMLN). In a research report published today, Citi commented on the company's new drug Bydureon. In the report, Citi states, “Amylin presented a poster at the ADA meeting showing the QTcF (heart conduction) data on Bydureon… The data showed...